Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: ICON
Ticker:iclr
Yahoo Beta:0.49
Industry:biotechnology and drugs

Company Description:  ICON plc is a contract research organization that supports phase 1 through phase 4 clinical trials for new drugs. ICON, the number 4 CRO world-wide, is based in Ireland.

Purchase Date:25 Sep 2020 Sale Date:30 Aug 2021
Purchase Price:$180.99 Sale Price:$255.45
  --Split Adjusted:$180.99  --Split Adjusted:$255.45
Shares Purchased:16 Shares Sold:16
  --Split Adjusted:16  --Split Adjusted:16
Transaction Fee:$81.85 Transaction Fee:$13.74
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$196.10 High$0.00
Date22 Jul 2020 Date01 Jan 1996
Low$129.79 Low$0.00
Date02 Apr 2020 Date01 Jan 1996
S&P (Purchase Date):$3,267.37 S&P (Sale Date):$4,534.53

Purchase
Timing:  We bought above the midpoint of the six-month range.
Reason:  Icon has continued to be a strong performer. We anticipate that demand for clinical trials will continue to be robust, particularly in the era of COVID-19.

Sale
Timing:  x
Reason:  We sold to generate cash for the annual rebalancing.

S&P Gain: 38.78 % Annualized Gain: 47.46%
Stock Gain: 41.14 % Annualized Gain: 50.43%

Dividends:$0.00
Net Holding Return ($): $1,095.77
Net Holding Return (%): 36.8 %